Platelet activating factors are associated with depressive symptoms in coronary artery disease patients: a

Graham Mazereeuw1, Nathan Herrmann2, Hongbin Xu3

  • 1Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON, Canada ; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada ; CIHR Training Program in Neurodegenerative Lipidomics, Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, Ottawa, ON, Canada.

Insights

Depression in coronary artery disease (CAD) patients may be linked to specific platelet-activating factor (PAF) lipids. Higher levels of certain PAF species in the blood correlated with increased depressive symptom severity in CAD individuals.

Area of Science:

  • Cardiovascular Medicine
  • Neuroscience
  • Biochemistry

Background:

  • Depression frequently complicates coronary artery disease (CAD), but its causes remain unclear.
  • Platelet-activating factor (PAF) lipids, implicated in CAD, are being investigated for their role in depression through mechanisms like inflammation and oxidative stress.

Purpose of the Study:

  • To investigate the association between specific platelet-activating factor (PAF) lipid species and depressive symptom severity in patients with coronary artery disease (CAD).

Main Methods:

  • The study analyzed plasma samples from 26 CAD patients using high-performance liquid chromatography electrospray ionization mass spectrometry.
  • Depressive symptoms were assessed using the Hamilton Depression Rating Scale (HAM-D).

Main Results:

  • Significant positive correlations were found between depressive symptom severity (HAM-D score) and plasma levels of specific PAF species: PC(O-12:0/2:0), PC(O-14:1/2:0), PC(O-17:3/2:0), and PC(O-18:3/2:0).
  • These associations remained significant after adjusting for patient age and sex.

Conclusions:

  • Preliminary findings suggest that the PAF lipidome may hold potential as a source of biomarkers for depressive symptoms in individuals with CAD.
  • Further exploration of PAF lipid species is warranted for understanding and potentially treating depression in CAD patients.
Abstract

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
857
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
751
Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
674
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.7K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
992
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K